As evogliptin, one of the DPP-4 inhibitors displays high specific accumulation in cardiac tissue, we here evaluated its therapeutic potency for attenuating valvular calcification in CAVD animal models. This evidence concerns the gene DPP4 and congenital bilateral aplasia of vas deferens from CFTR mutation.